PRIMARY STUDY
Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease.
Key Findings: Downregulation of CB2 receptors has been reported in the brains of PD patients. Therefore, both the activation and the upregulation of the CB2 receptors are believed to protect against the neurodegenerative changes in PD. The present study suggests that BCP has the potential therapeutic efficacy to elicit significant neuroprotection by its anti-inflammatory and antioxidant activities mediated by activation of the CB2 receptors.
Type of Study: Animal Study
Study Result: Positive
Cannabinoids Studied: AM-x Synthetic Cannabinoids
Phytocannabinoid Source: Not Applicable
Form of Administration: Injection
Dosage: BCP was diluted in olive oil and administered i.p. at a dose of 50 mg/kg BW once daily for 4 weeks, 30 min prior to rotenone (ROT) administration in the presence or absence of AM630, a CB2 receptor antagonist.
Terpenes Studied: ß-Caryophyllene
Receptors Studied: CB2
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Study Location(s): Australia, Italy, United Arab Emirates
Year of Pub: 2016
Link to study